Madam Chair, our top priority is to access safe and effective vaccines for Canadians. Supporting domestic vaccine projects has been an important part of our strategy. We have spent over a billion dollars in support of early stage research on COVID-19 clinical trials of domestic vaccine candidates and the expansion of domestic bio-manufacturing capacity.
As an example, on October 23, we announced an investment of $173 million in Quebec City-based Medicago. This funding will help to advance the company's vaccine candidates through clinical trials.
Our portfolio is among the best in the world. We have more doses per capita than any other country.
On the member's earlier statement—